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The satiating hormone amylin enhances
neurogenesis in the area postrema of adult rats
Claudia G. Liberini 1,2,3, Tito Borner 1,2, Christina N. Boyle 1,*, Thomas A. Lutz 1,2
ABSTRACT
Objective: Adult neurogenesis in the subgranular zone and subventricular zone is generally accepted, but its existence in other brain areas is still
controversial. Circumventricular organs, such as the area postrema (AP) have recently been described as potential neurogenic niches in the adult
brain. The AP is the major site of action of the satiating hormone amylin. Amylin has been shown to promote the formation of neuronal projections
originating from the AP in neonatal rodents but the role of amylin in adult neurogenesis remains unknown.
Methods: To test this, we ﬁrst performed an RNA-sequencing of the AP of adult rats acutely injected with either amylin (20 mg/kg), amylin plus
the amylin receptor antagonist AC187 (500 mg/kg) or vehicle. Second, animals were subcutaneously equipped with minipumps releasing either
amylin (50 mg/kg/day) or vehicle for 3 weeks to assess cell proliferation and differentiation with the 50-bromo-2-deoxyuridine (BrdU) technique.
Results: Acute amylin injections affected genes involved in pathways and processes that control adult neurogenesis. Amylin consistently
upregulated NeuroD1 transcript and protein in the adult AP, and this effect was blocked by the co-administration of AC187. Further, chronic
amylin treatment increased the number of newly proliferated AP-cells and signiﬁcantly promoted their differentiation into neurons rather than
astrocytes.
Conclusion: Our ﬁndings revealed a novel role of the satiating hormone amylin in promoting neurogenesis in the AP of adult rats.
 2016 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. INTRODUCTION
Amylin is a pancreatic hormone whose role in the control of food intake
and energy metabolism is well characterized [1e6]. In response to
nutrient stimulation, amylin is co-secreted with insulin from the b-cells
[2], whereby it acts to slow glucose appearance by reducing food
intake, inhibiting glucagon secretion, and slowing gastric emptying
[7,8]. Amylin’s effects are primarily mediated via the area postrema
(AP), a sensory circumventricular organ (CVO) located at the infer-
oposterior border of the fourth ventricle in the hindbrain. AP-neurons
express amylin receptors, which comprise a calcitonin receptor
(CTR) core and one or more members of the receptor activity-modifying
proteins (RAMPs) [9e12]. Amylin treatment activates the extracellular
signal-regulated kinase 1 and 2 (ERK 1/2) signaling pathway in CTR-
positive AP neurons, which may contribute to its satiating effect
[13]. Further, we recently showed that acute amylin differentially
regulates the transcription of its own receptor components (RAMPs)
and of the leptin receptor in the AP of adult rats [12].
While amylin’s role in energy homeostasis is perhaps the most studied,
growing evidence suggests that the hormone may have additional
beneﬁcial effects in the brain. Neonatal amylin-deﬁcient mice have a
reduced density of neuronal projections from the AP, suggesting
amylin’s potential to function as a trophic factor [14]. Amylin may also
exert neuroprotective effects in the brain. Chronic treatment with the
amylin analog pramlintide improved memory, cognition, and amelio-
rated hippocampal pathology in a mouse model of Alzheimer’s disease
[15]. Chronic treatment with amylin could also rescue reduced cell
proliferation observed in the hippocampus and AP following ovariec-
tomy in adult female rats [16].
At present, little is known about the mechanism by which amylin
causes these neuronal changes, notably the neurogenic effects
observed in the adult brain. In has been shown recently that several
CVOs, including the AP, contain the machinery necessary for the birth
of new neurons, including neural stem cells (NSC), and that adult
neurogenesis constitutively occurs in these nuclei [16e19]. As
observed in the classic neurogenic niches of subgranular zone of the
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hippocampus [20,21] and the subventricular zone lining the lateral
ventricle [22], adult-born cells in the mammalian brain are guided
through proliferation, differentiation and survival by speciﬁc extracel-
lular and intracellular programs [23]. Upregulation of the proneural
basic helix-loop-helix (bHLH) transcriptional factor NeuroD1 (Neuronal
differentiation-1, also known as Beta2) alone is sufﬁcient to induce the
differentiation of adult hippocampal neural progenitors into neurons
[24,25], whereas the deletion of NeuroD1 from these neurogenic
niches resulted in a signiﬁcant reduction of new neurons [25]. Further,
growing evidence supports the role of Ephrin-signaling and gamma-
amino-isobutyric acid (GABA) signaling in the control of multiple
steps of adult neurogenesis [26e28].
It is unclear if these pathways are also involved in adult neurogenesis in
the AP, and whether amylin might activate them to promote the birth of
new cells. There are several reports, however, demonstrating that
signals related to nutrient status can inﬂuence adult neurogenesis.
Metabolic hormones like insulin, leptin, and ghrelin have all been shown
to induce neurogenesis in the hippocampus [29e32]. It was also shown
recently that consumption of a high fat diet increases neurogenesis in
the hypothalamic median eminence (ME) [33]. Like insulin and leptin,
amylin levels are elevated in states of positive energy balance, and
could therefore be another nutritional signal driving the generation of
newborn neurons in metabolic centers in the brain [34].
In the present study we therefore asked whether acute and chronic
amylin administration might inﬂuence adult neurogenesis in the AP. To
address these questions, we ﬁrst performed an RNA-sequencing
experiment to determine the genes differentially regulated by acute
amylin treatment. Further, we analyzed the chronic amylin-mediated
effects on cell proliferation and differentiation in the AP of adult rats
by BrdU-labeling and double-ﬂuorescent immunohistochemistry
techniques.
2. ANIMALS, MATERIALS AND METHODS
2.1. Animals and housing
Adult male Wistar rats (Janvier, Le Genest Saint Isle, France) (220e
250 g) were used for the experiments and were single-housed in a
temperature-controlled environment (21  1 C) on an artiﬁcial 12 h/
12 h light/dark cycle. Rats had ad libitum access to water and standard
chow (no. 3430; Provimi Kilba, Gossau, Switzerland), except during
fasting periods as described below. All procedures involving animals
and their care were approved by the Veterinary Ofﬁce of the Canton
Zurich, Switzerland, and in accordance with the EU Directive 2010/63/
EU on the protection of animals used for scientiﬁc purposes.
2.2. Drugs
Amylin (Bachem AG, Bubendorf, Switzerland; catalog number: H-
9475.1000) was reconstituted in sterile 0.9% NaCl, AC187 (TOCRIS
Bioscience, Bristol, UK; catalog number: 3419) was reconstituted in
sterile double-distillated water. BrdU (B5002, Sigma Aldrich, Buchs,
Switzerland) was dissolved in sterile double-distillated water and
heated to 40e50 C.
2.3. Experiment 1: next generation sequencing (NGS) of the entire
AP
Rats (220e250 g; n ¼ 5 per group) were fasted for 12 h during the
light phase. At dark onset, rats were acutely treated intra-peritoneally
(i.p.) with amylin (20 mg/kg), amylin plus the amylin receptor antag-
onist AC187 (500 mg/kg) or with vehicle (NaCl). Ninety minutes after
drug administration, rats were anesthetized with isoﬂurane and
decapitated; during this 90-min period, rats had no access to food.
2.3.1. RNA extraction
After decapitation, the AP was surgically removed from the hindbrain
under a light microscope and RNA was extracted according to man-
ufacturer’s instructions (TRI Reagent; SigmaeAldrich, Buchs,
Switzerland) and then puriﬁed following the cleanup protocol of
RNeasy Mini kit (Qiagen, Basel, Switzerland), including the DNase
step. The concentration and the integrity of RNA were measured using
a nanodrop system (NanoDrop 1000 Spectrophotometer, Thermo
Scientiﬁc, Waltham, MA, USA).
2.3.2. Strand-speciﬁc cDNA library construction
From each sample, 10 ng of total RNA were taken to construct strand-
speciﬁc cDNA libraries using the Ovation Single Cell RNA-Seq System
(PART NO. 0342, NuGEN; San Carlos, California). The quality of cDNA
libraries was tested and quantiﬁed cDNA was subjected to puriﬁcation,
elution, end-repair and adapter ligation. A second round of library
ampliﬁcation and puriﬁcation was performed, following the manufac-
turer’s instruction. Samples were screened by bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA) and qPCR. The established cDNA
libraries were sequenced using the Illumina HiSeq 2000 platform
(Ilumina Inc., San Diego, CA, USA) to generate 100 bp paired-end
reads.
2.3.3. Enrichment analysis for pathways, gene ontology (GO)
processes and gene network construction
The list of ranked genes for each sequencing batch and the list of
susceptibility genes were imported into MetaCore software version
6.24 (Thomson Reuters, New York, NY, USA). Enrichment analysis for
pathways and GO processes was performed on gene expression data
to identify signiﬁcant pathways and processes affected by our
experimental conditions. Enrichment analysis comprised both up- and
down-signals, distribution was achieved by intersection setting and the
sorting method was based on statistically signiﬁcant data
(threshold ¼ 2 and P-value  0.01). Analysis was performed via the
online platform portal.genego.com version 6.20.66481. To determine
the pathways associated with the susceptibility genes, a sub-
enrichment analysis was performed on the list of these genes. Path-
ways are represented by the GO set class of biological processes.
Finally, to determine the interactions between susceptibility genes
from the different functional groups, gene networks were constructed.
Data ﬁles were analyzed with MetaCore þ MetaDrug version 6.19
build 65960 scripts 65979.
2.3.4. Quantitative real-time PCR (qPCR)
Total RNA was reverse transcribed with Tetro cDNA Synthesis Kit
(Bioline, Elchrom Scientiﬁc AG, Cham, Switzerland). Real-time PCR
was performed using 7500 Fast system (Applied Biosystem/Life
Technologies Carlsbad, CA, USA) with QuantiTect SYBR green PCR
kit (Qiagen, Basel, Switzerland). Intron-spanning primers were
designed with IDT, Integrated DNA Technologies, (http://eu.idtdna.
com). The primer sequences were the following: for rat GAPDH, for-
ward: 50-AGACAGCCGCATCTTCTTGT-30 and reverse: 50-
CTTGCCGTGCGTAGAGTCAT -30 (Accession: NM_017008.4); for rat
NeuroD1, forward: 50-GAACACGAGGCAGACAAGAA-30 and reverse: 50-
TCATCTTCATCCTCCTCCTCTC-3’ (Accession: NM_019218.2). 100 ng
of cDNA were subjected to an initial heat activation at 95 C for 15 min,
followed by 40 cycles of alternating between 94 C for 15 s, 60 C for
30 s, and ﬁnal extension at 72 C for 30 s. The fold change in
expression of each gene was calculated using the comparative DDCt
method, with GAPDH as endogenous control. Each sample was run in
duplicate.
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2.4. Experiment 2: validation of NGS ﬁndings
The second experiment aimed to further validate the difference in
NeuroD1 transcript at the protein level. Rats (220e250 g; n ¼ 3 per
group) were fasted during the light phase and acutely treated with
amylin (20 mg/kg; i.p), or with vehicle (NaCl; i.p). Ninety minutes after
drug administration, animals were deeply anesthetized with sodium
pentobarbital (100 mg/kg; i.p.) and transcardially perfused using 0.1M
PB followed by 4% paraformaldehyde (PFA). During this 90-min period,
rats had no access to food.
The brains were collected and maintained overnight in 4% PFA.
Subsequently, the brains were transferred to 20% sucrose in PBS for
24 h. Brains were cut into 20-mm coronal sections on a cryostat (Leica
microsystem, Wetzlar, Germany) and stored in cryoprotectant (20%
glycerol, 30% ethylene glycol, 50% 0.1M PB) until processing for
immunohistochemistry.
2.4.1. Immunohistochemistry
Slide-mounted sections (20 mm) were washed in 0.1M PBS (pH 7.4)
and then incubated in immunoblocking buffer (2.5% bovine serum al-
bumin [BSA], 0.1% Triton X-100 in PBS) for 1 h at room temperature.
Subsequently, sections were incubated with Rabbit anti-NeuroD1 pri-
mary antibody (1:250, Abcam, Cambridge, UK). After overnight incu-
bation at 4 C, the sections were washed in PBS and incubated for 3 h
with ﬂuorescent secondary antibody Alexa Fluor 488 Donkey anti-rabbit
immunoglobulin G (IgG) (1:400, Invitrogen, MOLECULAR PROBES,
Eugene, Oregon, USA). The nuclear dye DAPI (40,6-diamidino-2-
phenylindole; SigmaeAldrich, Buchs, Switzerland) was added to sec-
ondary antibodies solution for nuclear staining. Sections were then
rinsed in PBS and coverslipped with ﬂuorescent mounting medium.
2.5. Experiment 3: effect of chronic amylin treatment on cell
proliferation and differentiation in the adult AP
Rats (220e250 g; 4 groups and n¼ 8 per group) were acclimatized in
their home-cage environment. Amylin (50 mg/kg/d) or vehicle was
chronically administered peripherally by subcutaneous osmotic mini-
pumps (Alzet, Model 2004 ensuring up to 3-week constant delivery
of the pre-charged solution; Durect Corporation; Cupertino, CA, USA)
for seven days or three weeks, respectively. On the day of implanta-
tion, the minipumps were ﬁlled under sterile conditions with saline or
amylin. Rats were initially anesthetized by inhalation of 5% isoﬂurane
(IsoFlo, Provet AG, Lyssach, Switzerland), then maintained on 2e3%
isoﬂurane and placed on a heating pad to maintain body temperature
during surgery. At the site of implantation, rats were shaved and the
skin was disinfected with Betadine (Provet AG, Lyssach, Switzerland).
Under sterile conditions, a small incision was made between the
scapulae and the minipump was subcutaneously implanted. The
wound was closed with interrupted cutaneous sutures. Food intake
and body weight were measured daily.
2.5.1. BrdU injection
BrdU was used to track cell proliferation and differentiation. Rats were
given twice daily i.p injections of BrdU (75 mg/kg; 12 h apart) for 6 days,
starting on the day of minipump implantation. To determine the rate of
newborn cells, part of the rats were sacriﬁced on day 7 (i.e. 12 h after
the last BrdU injection); the remaining rats were allowed to survive for
an additional two weeks and then sacriﬁced at the end of the 3-week
amylin infusion period, to investigate the fate of the BrdU-labeled cells.
2.5.2. Tissue preparation
Animals were perfused and brains processed following the protocol
described in Experiment 2 (Section 2.4), with two exceptions: here,
tissues were stored in a solution of 30% sucrose in PBS for 48 h and
brains were cut into 30-mm coronal sections.
2.5.3. Double ﬂuorescence immunohistochemistry
Free-ﬂoating sections were pretreated to denature the DNA to make
the BrdU antibody detectable. Brieﬂy, AP sections were incubated in a
solution of 50% formamide for 2 h at 65 C; then, sections were
incubated in 2N HCl for 30 min at 30 C and subsequently acid
neutralized with 0.1 M borate buffer for 10 min. After washing in 0.1M
PBS (pH 7.4), sections were incubated in immunoblocking buffer (3%
goat serum, 1% BSA, 0.3% Triton X-100 in PBS) for 1 h. Primary
antibodies were applied as a cocktail that included rat anti-BrdU pri-
mary antibody (1:100, Abcam, Cambridge, UK), mouse anti-HuCD
(1:100, Thermo Fisher Scientiﬁc, Wahltman, MA, USA), rabbit anti-
DCX (1:1000, Abcam, Cambridge, UK), rabbit anti-GFAP (1:1000,
Abcam, Cambridge, UK), mouse anti-RECA-1 (1:2000; AbD Serotec,
Kidlington, UK) or rabbit anti-calretinin (CR) (1:100, Abcam, Cam-
bridge, UK). After overnight incubation at 4 C, the sections were
washed in PBS and incubated for 4 h with ﬂuorescent secondary
antibodies, also applied as a cocktail: Alexa Fluor 488 goat anti-rat
immunoglobulin G (IgG) to reveal immunoreactivity of BrdU and
Alexa Fluor 555 goat anti-rabbit to reveal immunoreactivity of either
GFAP, RECA, DCX and CR IgG, or Alexa 555 goat anti-mouse to reveal
immunoreactivity of HuCD (1:400 for all the antibodies; Invitrogen,
MOLECULAR PROBES, Eugene, Oregon, USA). Then, the sections
were rinsed in PBS and mounted onto Superfrost glass slides (Thermo
Scientiﬁc, Waltham, MA USA) and coverslipped with ﬂuorescent
mounting medium.
2.6. Cell quantiﬁcation and analysis
Two AP sections per brain were counted and averaged to determine
the number of NeuroD1-positive cells per animal in Experiment 2, and
BrdU-labeled cells and the total number of neurons and glia, in
Experiment 3. Counting was accomplished at 20 magniﬁcation and
numerical aperture of 0.5, using a light microscope (Zeiss Imager Z2;
Carl Zeiss, Jena, Germany) equipped with a color camera (Zeiss Axi-
ocam; Carl Zeiss, Jena, Germany). The number of NeuroD1-positive
cells (i.e; number of particles) and the total number of neuronal and
glial cells (i.e; density of particles) was quantiﬁed with Image J version
1.49b. BrdU-labeled cells were manually counted by eye. For cell
differentiation experiments, ﬂuorescent double-labeled sections with
BrdUþ/HuCDþ cells and BrdUþ/GFAPþ cells were visualized and
analyzed on CLSM Leica TCS SP8 upright confocal microscope (Leica
Microsystem, Wetzlar, Germany) equipped with an x-y-z motorized
stage and three lasers (Argon 488, HeNe 543 and HeNe 633) appro-
priate to detect DAPI, Alexa 555 and Alexa 488 ﬂuorescence,
respectively. Each laser channel was separately scanned using a
multitrack PMT conﬁguration to avoid cross-talk between ﬂuorescent
labels. A careful examination of all secondary antibodies was per-
formed to avoid any possible cross-talk between ﬂuorescent dyes or
any cross-reactivity between secondary antibodies. To evaluate
double-labeling, confocal z-stack sectioning was performed at 0.5e
1.0-mm intervals using 40  oil-immersion (NA ¼ 1.30) or 63  oil-
immersion (NA ¼ 1.40) objectives. Images were acquired and 3D-
reconstructed using the Zeiss LSM software, cropped and optimized in
Imaris Software version 6.4.0 (Bitplane AG, Zurich, Switzerland).
Colocalization of BrdU with HuCD or GFAP, respectively, was conﬁrmed
by examining multiple optical planes for each cell on the z-axis. The
percentage of BrdU-positive cells double-labeled for HuCD or GFAP
was determined by eye counting. The experimenter was blinded to the
treatment (amylin versus control).
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2.7. Statistical analysis
Relative mRNA expression levels were assessed by one-way ANOVA.
BrdU-labeled cells and food intake were quantiﬁed and then compared
using Student’s t-test or one-way-ANOVA, as appropriate, by using
GraphPad Software version 6.0 (San Diego, CA, USA). All values are
expressed as mean  S.E.M. The level of signiﬁcance was set to
P < 0.05.
3. RESULTS
3.1. Acute amylin treatment affected the regulation of genes
involved in pathways and processes that participate in the regulation
of neurogenesis
We recently demonstrated that acute amylin treatment regulates the
transcription of speciﬁc genes in the AP that are involved in amylin
signaling at the single cells level [12]. We therefore aimed to determine
whether amylin also has the ability to modulate the entire tran-
scriptome of the AP. Pathways analysis performed on the NGS data
revealed that Cell adhesion_Ephrin signaling, neurophysiological
process_GABAA-receptor life cycle and neurophysiological process_
GABAB-receptor signaling at postsynaptic sides of the synapsis path-
ways were the top-three pathways which involved genes affected by
acute amylin treatment (Table 1).
GO analysis strengthened and expanded the results obtained with the
pathway analysis. GO analysis described a scenario in which most of
the genes that were affected by amylin in the adult AP are involved in
processes such as neurogenesis, synaptic transmission, nervous
system development, cellecell signaling and generation of neurons
(Table 2). The cross analysis between pathways and GO processes
was used to generate a gene network of the major targets affected by
our experimental conditions. The resultant gene map conﬁrmed that
acute amylin treatment inﬂuenced the Ephrin and GABAA gene families.
Moreover, the network analysis revealed that NeuroD (Neuronal-dif-
ferentiation) and Wnt (Wingless-Type MMTV Integration Site Family)
gene families are present and integrated in the network of genes
affected by amylin in the AP of adult rats (Figure 1).
3.2. Acute amylin administration signiﬁcantly upregulated NeuroD1
transcript and protein in the AP of adult rats, and this response was
completely blocked by the administration of AC187
Results from the GO enrichment analysis (Table 2) showed that the
majority of the genes identiﬁed via the NGS are involved in
neurogenesis-like processes; further, the gene network (Figure 1)
described a scenario in which NeuroD1 may interact, via canonical and
unknown pathways, with Wnt, EphRs and GABAA-receptors signaling
to mediate amylin’s effect on neurogenesis-like processes. Therefore,
we further validated the effect of amylin on NeuroD1 mRNA expression
by qPCR and found that acute amylin treatment signiﬁcantly upregu-
lated NeuroD1 transcript levels about 13 fold. This effect was
completely reversed by in vivo co-application of the amylin receptor
antagonist AC187 (Figure 2A; One-way ANOVA; F(2,12) ¼ 18.96,
***P¼ 0.0002). We conﬁrmed the upregulation at the protein level and
showed that rats (n ¼ 3 per group) that were acutely treated with
amylin exhibited a marked upregulation of NeuroD1 compared to
controls (Figure 2BeD; Student’s t-test; t4 ¼ 9.774, ***P ¼ 0.0006).
3.3. Chronic amylin treatment signiﬁcantly increased the number
of newly proliferated (BrdU-labeled) cells after one-week treatment
in the AP of adult rats
To further investigate a direct role of amylin in adult neurogenesis,
animals (n¼ 8 per group) were chronically treated with amylin (50 mg/
kg/d) or vehicle. Food intake was measured daily throughout the
experiment; as expected [4], amylin effectively decreased 24-hour
food intake (but not body weight) compared to controls (Student’s t-
test; t14 ¼ 2.574, *P < 0.05; Supplementary Figure 1a,b).
Based on the premise that new cells are continuously generated in the
AP of adult rats [17,18], we examined the number of newly prolifer-
ating cells by analyzing BrdU-immunoreactive (BrdU-labeled) cells in
vehicle (Figure 3A) and amylin-treated animals (Figure 3B). After one-
week of amylin infusion, the number of BrdU-labeled cells was
signiﬁcantly increased compared to controls (Student’s t-test;
t12 ¼ 3.978, **P ¼ 0.0018; Figure 3C). This suggests that chronic
amylin treatment may be sufﬁcient to affect and enhance the gener-
ation rate of adult-born cells.
3.4. BrdU-labeled cells predominantly differentiated into neurons
after three-weeks of chronic amylin treatment in the AP of adult rats
To determine the cell fate of the newly born cells in adult rats, we
performed a series of immunohistological double-label staining using
different cellular markers after three weeks of amylin treatment
(Figure 4). Immature and mature neurons were stained with the
Table 1 e Enrichment analysis by pathway.
Pathway maps *Total P-value FDR
Cell adhesion_Ephrin signaling 45 1.384E-07 2.076E-05
Neurophysiological process_GABA-A
receptor life cycle
27 4.311E-06 7.674E-04
Neurophysiological process_GABA-B
receptor signaling at postsynaptic sides of
synapses
42 2.628E-05 2.339E-03
Neurophysiological process_Dopamine D2
receptor signaling in CNS
47 4.125E-05 2.448E-03
Signal transduction_PKA signaling 51 5.711E-05 2.541 E-03
Neurophysiological process_Receptor-
mediated axon growth repulsion
45 1.010E-04 7.573E-03
Neurophysiological process_Dopamine D2
receptor transactivation of PDGFR in CNS
26 1.530E-04 1.683E-02
Neurophysiological process_HTR1 A receptor
signaling in neuronal cells
26 1.530E-04 1.683E-02
G-protein signaling_G-Protein alpha-i
signaling cascades
27 1.856E-04 6.608E-03
Neurophysiological process_Mu-type opioid
receptor-mediated analgesia
30 2.554E-04 7.578E-03
*Total refers to the total number of genes involved in a pathway. False discovery rate
(FDR) and P-value refer to pathways involved in the experimental conditions. A P-value
<0.01 is considered signiﬁcant.
Table 2 e Enrichment analysis by GO processes.
Processes *Total P-value FDR
Synaptic transmission 874 6.897E-33 2.664E-29
Nervous system development 2841 4.102E-30 7.922E-27
Cellecell signaling 1293 6.233E-28 9.147E-25
Neurogenesis 1969 5.902E-21 5.698E-18
Neurotransmitter transport 185 1.526E-20 1.179E-17
System development 5219 2.760E-20 1.776E-17
Neurotransmitter secretion 133 3.607E-20 1.990E-17
Regulation of neurotransmitter levels 190 4.640E-19 1.792E-16
Generation of neurons 1871 7.046E-19 2.474E-16
Neuron differentiation 1405 2.870E-18 9.237E-16
*Total refers to the total number of genes involved in a process. FDR and P-value refer
to processes involved in the experimental conditions. A P-value <0.01 is considered
signiﬁcant.
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neuronal marker HuCD (Figure 4B,E) and BrdUþ/HuCDþ double-labeled
cells were mainly present in the central region of the AP (Figure 4F).
Glial cells were identiﬁed with the glial marker GFAP (Figure 4H,K) and
BrdUþ/GFAPþ double-labeled cells were predominantly located at the
borders of the AP (Figure 4I,L). The number of BrdU-labeled cells was
higher in rats chronically treated with amylin compared to controls
(Student’s t-test; t15 ¼ 2.163, *P ¼ 0.0471; Figure 5A). Moreover,
amylin signiﬁcantly increased the number of BrdUþ/HuCDþ double-
labeled cells, compared to control (Student’s t-test; t15 ¼ 6.059,
*P < 0.0001; Figure 5B). Finally amylin signiﬁcantly raised the per-
centage of double-labeled cells in respect to the percentage of BrdU-
positive cells (Student’s t-test; t15 ¼ 5.563, *P < 0.0001; Figure 5C).
The number of newly generated cells is not only a function of cell
proliferation and migration, but also of cell death. To exclude any
potential toxic effects of chronic amylin treatment on neuronal survival,
we quantiﬁed the total number of mature and immature neurons in the
AP of animals after 3-weeks of amylin or vehicle treatment. Our results
reported no signiﬁcant difference in the number of immature and
mature neurons comparing amylin versus vehicle-treated animals;
suggesting that chronic amylin infusion has no toxic effect on the
neuronal survival in the AP of adult rats (Student’s t-test; t10 ¼ 0.828,
P ¼ 0.4267; Figure 5D). Moreover, chronic amylin treatment did not
induce any gliosis in the AP of adult rats (Student’s t-test; t13¼ 1.607,
P ¼ 0.1320; Figure 5E).
Figure 1: Top gene map in response to acute amylin. Network analysis (generated with MetaCore þ MetaDrug) of the genes whose expression was affected by amylin treatment
is shown. Major functions of the network are indicated. See the bottom ﬁgure legend for details.
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Finally, we further conﬁrmed the double-staining observed under ﬂuo-
rescence microscope (Figure 6A) by confocal quantiﬁcation. Our results
showed that amylin preferentially induced a neuronal rather than glial
cell fate (One-way ANOVA; F(3,28)¼ 27.51; ****P< 0.0001; Figure 6B).
To conﬁrm a chronic amylin effect, food intake and body weight were
monitored daily during the experiment. 24-hours food intake (but not
body weight) was signiﬁcantly decreased by amylin during the three-
week treatment period (Student’s t-test; t14 ¼ 2.718, *P ¼ 0.0167;
Supplementary Figure 1c,d). Ultimately, to exclude a possible co-
localization of BrdU-labeled cells with interneurons or blood vessels,
we performed immunohistochemical analysis for the interneuron
marker CR (Supplementary Figure 2aef) and the blood-vessel marker
RECA-1, respectively (Supplementary Figure 2gel). We did not detect
any co-localization of BrdU-labeled cells with CR (Supplementary
Figure 2f), indicating that chronic amylin does not seem to promote
the differentiation of newborn cells into interneurons in the AP.
Abundant RECA-1 staining was found in the AP, conﬁrming its highly
vascularized structure (Supplementary Figure 2h,k); however, no co-
localization between BrdU and RECA-1 was detected in the AP of
adult rats (Supplementary Figure 2i,l).
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Figure 2: NeuroD1 mRNA and protein expression was signiﬁcantly increased by acute amylin treatment, and reversed by the amylin antagonist AC187. (A) qPCR analysis showing
NeuroD1 mRNA expression levels after vehicle, amylin (20 mg/kg) or amylin þ AC187 (500 mg/kg) treatments (n ¼ 5 rats per group). Amylin consistently and signiﬁcantly up-
regulated NeuroD1 mRNA expression compared to vehicle. AC187 reversed the amylin effect (One-way ANOVA, ***P ¼ 0.002). mRNA levels are shown as fold change and GAPDH
is used as internal control. Data are expressed as mean  S.E.M. (B) Quantiﬁcation of NeuroD1 protein. (C) Immunohistochemistry of NeuroD1 in AP sections of a vehicle (C) and
amylin (D) treated rat, respectively. The inset shows co-localization of NeuroD1 and DAPI. Scale bar represents 50 mm.
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Figure 3: Amylin (50 mg/kg/d) increased the number of BrdU-positive cells after one week of treatment. (A) Immunohistochemical staining of BrdU-positive cells in AP sections of
vehicle (A) and amylin (B) treated rats, respectively (n ¼ 8 rats per group). (C) Amylin signiﬁcantly increased the number of BrdU-immunoreactive cells compared to control
(Student’s t-test; **P ¼ 0.0018). Data are expressed as mean  S.E.M. Scale bar represents 50 mm.
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4. DISCUSSION
The present ﬁndings further substantiate amylin’s role as a promoter of
neurogenesis in the AP of adult rats. First, our NGS analysis demon-
strated that acute amylin administration modulates genes involved in
pathways and processes that regulate different steps of both post-
natal and adult neurogenesis in the AP of adult rats. Second, chronic
administration of amylin increased the number of newly proliferated
cells in the AP and promoted their differentiation predominantly into
neurons rather than astrocytes. Finally, the validation of the NGS re-
sults supports the idea that NeuroD1 underlies the neurogenic effects
of amylin in the AP.
Speciﬁcally, our NGS data showed that signaling pathways that guide
all the stages of neurogenesis from birth through maturation, such as
Ephrin-, GABA- and Wnt-signaling, are affected by acute amylin
treatment. Our results also revealed that amylin triggers the upre-
gulation, and possibly the activation, of NeuroD1 mRNA and protein in
the AP of adult rats. Co-administration with the amylin receptor
antagonist AC187 blocked this amylin-induced increase of NeuroD1,
suggesting a direct role of amylin on NeuroD1 expression in this brain
area. As the current study did not investigate whether the upregulation
of NeuroD1 is required for neurogenesis in the AP, additional exper-
iments involving mouse models of conditional NeuroD1-deﬁciency are
critically important [25].
Moreover, our study strengthened and expanded previous ﬁndings
describing that the AP of adult rats, like other CVOs, contains consti-
tutively proliferating cells that differentiate into neurons and astrocytes
[17,33]. The observed in vivo increase in BrdU-labeling in the presence
of chronic amylin therefore points to the promoting role of amylin in the
control of AP-cell proliferation. Importantly, the amylin-mediated
acquisition of a neuronal fate of the adult-born BrdU-labeled cells,
adds novel ﬁndings to the effects of amylin in the AP. In fact, standard
and confocal ﬂuorescent microscopy analysis demonstrated that the
majority of newly proliferated cells in the AP of adult rats differentiated
into neurons. Only a small percentage of adult-born cells, mainly those
located at the edges of the AP, differentiated into astrocytes three
weeks after amylin treatment. To exclude the possibility of a neurotoxic
role of chronic amylin infusion on AP-cells, we also demonstrated that
the total number of mature and immature neurons (HuCD-labeled cells)
and astrocytes (GFAP-labeled cells) in the AP of adult rats is not
Figure 4: BrdU-labeled cells in the AP of vehicle (A,G) and amylin (D,J) treated rats (n ¼ 8 per group); amylin was given for 3 weeks at a dose of 50 mg/kg/d. Sections stained for
neuronal (HuCD) and glia (GFAP) markers, respectively, are shown in (B,E,H,K). Newly generated BrdU-positive neurons double labeled for HuCD and GFAP are shown in (C,F) and
(I,L), respectively. The insets show examples of colocalization of BrdU and HuCD (F), which represent neurons, or colocalization of BrdU and GFAP (L), which represent glial cells.
Scale bar represents 50 mm.
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decreased by the administration of amylin. However, since the number
of proliferative cells is also function of cell death, further studies
investigating apoptotic processes will be required.
The novel actions of amylin characterized in this study raise several
questions regarding the functional and physiological role of amylin-
mediated increased neurogenesis in the AP of adult rats. At present,
the signiﬁcance of constitutive neurogenesis in the adult AP is poorly
understood. A potential explanation could be that the generation of new
neurons is required to control homeostasis. Speciﬁcally, the ongoing
neurogenesis might be responsible for a ﬁne control of food intake and
vomiting [1,35], two main actions controlled by the AP by a large
number of physiological or pathological stimuli. Hence, the necessity
for the constitutive neurogenesis in the adult AP might reside in the
“CVO-nature” of the AP. The lack of a BBB, and the possible negative
inﬂuence on AP-neurons due to blood-derived toxins might affect the
efﬁciency and survival of AP-neurons. Therefore, the presence of new
neurons in this brain area might suggest a protective mechanism of
neuronal replacement. Interestingly, other brain areas involved in
nutrient sensing and in the control of eating have also been reported to
show adult neurogenesis. In the arcuate nucleus of the hypothalamus,
the ciliary neurotrophic factor mediates continuous neurogenesis,
which has been shown to affect the long-term regulation of energy
balance [36]. In the adjacent ME, tanycytes from the ependymal zone
generate new neurons that contribute to the control of food intake and
development of obesity when mice were fed a high-fat diet [33]. The
ME also undergoes structural changes in response to metabolic
challenges, like fasting, which alter the accessibility of nutrients, such
as glucose, to neurons in the arcuate nucleus [37]. Amylin-induced
neurogenesis in the AP, which is structurally similar to the ME, with
tanycyte-like cells and fenestrated capillaries, might also facilitate
neuronal plasticity and proliferation required to maintain energy ho-
meostasis after metabolic challenges [38,39].
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Figure 5: Quantitative analysis of BrdUþ and double-labeled (BrdUþ/HuCDþ) AP-cells after 3 weeks of vehicle or amylin (50 mg/kg/d) treatment (n ¼ 8 rats per group). (A) Amylin
signiﬁcantly increased the number of BrdU-labeled cells after 3 weeks of treatment (Student’s t-test; *P < 0.05). (B) The number of double labeled cells (BrdUþ/HuCDþ) cells and
(C) the percentage of double-labeled BrdUþ/HuCDþ cells in respect to the total number of BrdUþ cells were increased after amylin treatment, compared to control (Student’s t-test;
****P < 0.001). (D) No difference in the total number of neurons or (E) glia was detected after 3-weeks of chronic amylin treatment. Data are expressed as mean  S.E.M.
A B
Figure 6: Quantiﬁcation of double-labeled cells. (A) Confocal z-stack image showing the co-localization of BrdUþ and HuCDþ cells. Scale bar represents 5 mm. (B) Number of
double-labeled BrdUþ/GFAPþ and BrdUþ/HuCDþ cells in the AP of adult rats. Adult-born cells preferentially committed to neuronal rather than glial fate after chronic amylin (50 mg/
kg/d) treatment (One-way ANOVA, B indicates signiﬁcant difference, ****P < 0.0001). Data are expressed as mean  S.E.M.
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How amylin exerts the aforementioned effects is unknown at present.
Our recent study demonstrated that more than one amylin receptor
subtype may be present in AP-neurons [12]. This suggests that
different amylin actions (for example, decreased food intake and
enhanced neurogenesis) might be mediated by different combinations
of the CTR/RAMPs complex. Which of these combinations may be
relevant for the neurogenic effect remains to be studied. Moreover, our
ﬁndings show that exogenous amylin increases neurogenesis, but we
did not directly assess the effect of endogenous amylin on adult
neurogenesis. Future BrdU-studies that test the effect of AC187 alone
on neurogenesis are needed to address this fundamental question.
A potential mechanism used by amylin to enhance adult neurogenesis
in the AP might involve amylin-induced activation of the ERK 1/2
cascade. Our own studies showed that acute amylin time and dose-
dependently activates ERK 1/2 signaling, by inducing ERK phosphor-
ylation, and that this effect contributes at least in part to amylin’s
satiating effect [13]. Since pERK-positive AP-neurons partially overlap
with the core subunit of the amylin receptor CTR [13], this effect seems
to be mediated by CTR-signaling. It has been shown that ERK1/2
knockout mice have impaired neurogenesis (as characterized by
abnormal laminar differentiation and marked reduction in neuronal size
in hindbrain nuclei), suggesting that ERK1/2 activity is required for the
generation of new neurons [40]. Moreover, recent ﬁndings demon-
strated that Wnt-mediated adult neurogenesis results in the upregu-
lation and activation of NeuroD1, possibly by triggering ERK-signaling
[41e44]. These ﬁndings therefore suggest that amylin may inﬂuence
AP-adult neurogenesis via ERK signaling.
To conﬁrm the presence of an amylin effect, food intake and body
weight were monitored daily throughout the course of the chronic
experiment. Average daily food intake was signiﬁcantly reduced in
amylin-treated rats compared to control. Unexpectedly, amylin did not
reduce body weight. As weight loss per se is known to induce neu-
rogenesis in the hippocampus [45], we can therefore exclude an effect
of decreased body weight as a source of increased neurogenesis in the
AP of adult rats. However, the exact relevance of amylin-induced
neurogenesis in the AP of adult rats in the context of feeding
behavior and the control of eating is not known at present. Since our
recent work demonstrated that amylin downregulates the subunits of
the amylin receptors [12], it seems possible that a chronic amylin
treatment might require an increased number of amylin-responsive
AP-neurons in order to mediate the satiating effect and thus a pro-
longed action on the metabolic circuits.
In conclusion, the present data further extend our understanding of the
amylin-mediated effects in the rodent AP. Our data demonstrate that
amylin regulates genes involved in pathways and processes that drive
neurogenesis in the adult mammalian brain. Our results also show an
in vivo increase in the number of newly proliferating AP-cells after
chronic amylin treatment. Moreover, amylin has the potential to
commit the AP adult-born cells to a neuronal fate. Amylin may
therefore be a novel target to be used to decipher the interaction
between neurogenic and metabolic circuits.
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